In Re ORTHOPEDIC BONE SCREW PRODUCTS LIABILITY LITIGATION, Plaintiffs Legal Committee, Appellant

FULLAM, Judge, District Senior

Concurring. In re ORTHOPEDIC BONE SCREW PRODUCTS LIABILITY judgment, I because we are concur LITIGATION, Astorri, panel opinion in v. bound U.S. (1991). believe, however, F.2d 1052 I Legal Committee, Appellant. Plaintiffs given panel, reasons the Astorri No. 97-1783. majority’s further elaboration of that

reasoning, are incorrect. Appeals, United States Court of Third Circuit. 3D1.2(c) clearly of the Guidelines

Section requires grouping of the counts this situa- Argued June 1998. tion, since the criminal conduct embodied Decided Nov. specific the mail fraud count is a offense Contrary characteristic of the tax count. majority, this does not in view

way frustrate the intent of the Commission harshly if

to treat tax cases more the unre- activity.

ported income came from criminal guideline range

The for the tax count is still points.

increased two And under the analysis, directly

grouping this would be re- sentence, in the actual if the tax count

flected

were the more serious of the two counts. anomaly perceived majority that, here,

entirely due to the fact the fraud higher guideline range,

count carries a sentencing mandatory.

concurrent aggravated

conduct which tax violation is punished

being in the fraud count. “specific

It should be noted all offense guideline range; enhance

characteristics”

accepting majority’s reasoning, there grouping

could never be of counts on that 3D1.2(c)

basis; Guideline be a would dead

letter. so, adopt

If free to I bright- do would espoused by

line rule the staff of the Com-

mission, accepted by our sister-circuit (5th Cir.1997). Haltom,

U.S. F.3d 43 not, respectfully suggest, I

This is an issue

which should divide the circuits. (Argued),

Michael D. Lev- Fishbein Arnold in, Levin, Fishbein, Berman, Sedran & Phila- PA, delphia, Appellant. for Feller, (Argued), S. Buresh Fred M. John Buresh, Austin, Kaplan, Jang, Feller & Noel, CA, Berkeley, P. George Noel & Hack- ett, PA, Media, Appellee for Buckman Co. Anthony (Argued), Pepper, Vale C.H. Scheetz, PA, Philadelphia, Hamilton & for Amicus-Appellees Inc., Danek Med. Sofamor SNC, Grp, Orthope- Sofamor Danek Warsaw Sofamor, dic Inc. Welsh, Jr., Recker,

Robert E. Welsh & PA, Philadelphia, Appellee Louis C. Bechtle. MaeDonell, Deutsch, L. Kerrigan

Janet & Stiles, Orleans, LA, Appellee New Sco- Society. liosis Research Jeddeloh, Radzius, Norman J. Burditt & IL, Chicago, Appellee Academy American Orthopaedic Surgeons. STAPLETON, Before: COWEN and RENDELL, Judges. Circuit THE OPINION OF COURT STAPLETON, Judge: Circuit This case thousands of involves individual plaintiffs-appellants they who claim that suf- injuries resulting implantation fered from the orthopedic pedicles bone screws into the 2,000 spines. their Over individual actions pre-trial proceedings were consolidated for pursuant litigation to the multi-district stat- ute, appeal U.S.C. This involves plaintiffs’ defendant, allegations that one (“Buckman”), Company, Buckman Inc. made misrepresentations Drug to the Food and (“FDA”) enough Administration serious play a substantial role in which the events injuries. resulted their The district court granted Buckman’s motion to dismiss this claim, state-law “fráü3Nm~the FDA” deter- mining “precluded that: the claim was MDA[i.e., virtue of the fact 1976, 21 Medical Device Amendments of 360e-360k, Food, §§ U.S.C. to the Federal (“FDCA”), Drug, and Cosmetic Act of 1938 seq.] 301 et provide 21 U.S.C. does not 157; action,” private right App. not, law, could as matter of of FDA hours review. See 518 U.S. at 477, 116 proximate demonstrate S.Ct. 2240. causation between misrepresentations important There are three exceptions to injuries App. suffered. at 158-59. We will requirement that Class III medical de- reverse. premarket vices receive approval before be-

ing placed First, on the market. a manufac- turer can obtain an Investigational Device I. Exemption (“IDE”), which allows limited use experimental anof medical gather device to A. type necessary the of data support pre- to orthopedic bone The devices that approval screw application. market See 21 U.S.C. subject are regulated by 360j(g). § the of this suit are Though IDE an allows use of a pursuant trials, the FDA to Class III Congress the MDA. device clinical it does not permit general the MDA to introduction to the public. enacted address concerns re garding safety and effectiveness of the Second, MDA allows Class III devices variety wide of medical devices introduced prior that were in commerce to its enactment Medtronic, into market. See Inc. v. remain to on the market until the FDA initi- Lohr, 470, 476, 518 U.S. 116 S.Ct. 135 completes premarket ates and approval (1996). L.Ed.2d 700 The requires clas MDA analysis “predicate” for those devices. See 360e(b)(l)(A). sification of medical § devices into three cate id. This “grandfathering” gories upon based they pose provision the risk that Congress’ to reflects recognition “that public. present existing Class I devices no unrea medical devices could not be with- drawn from the injury sonable risk of illness or market while the FDA and are com- sub pleted its PMA ject analysis for general to those manufacturing controls. devices.” Lohr, 477-78, 518 at 360c(a)(1)(A). U.S. 116 S.Ct. 2240. § See 21 U.S.C. Class II de potentially vices are more harmful and are Third, prevent to of grand manufacturers subject to performance regulations. federal fathered devices from monopolizing the mar 360c(a)(1)(B). § See Finally, id. Class III ket while new devices approval, wait for FDA “present[ potential a] devices unreasonable to improvements ensure that existing injury” risk of illness or subject and are are quickly, devices introduced the MDA al 360c(a)(1)(C). regulation. § the strictest lows devices that “substantially equiva Id. are existing predicate lent” to an device to avoid III Class devices introduced premarket approval process. Lohr, See into the market until the pro manufacturer 2240; 518 U.S. at 21 S.Ct. U.S.C. vides the FDA with “reasonable assurance” 360e(b)(1)(B). procedure § a manufac device is both safe and effective. advantage turer follows to take of this excep 360e(d)(2). § See “premarket ap id. This 510(k) is colloquially “§ known as the proval” process requires manufacturer to process,” after the number of the relevant submit, review, and the FDA to “all informa 510(k) original § appli section Act. A tion, published or known ... or which should must contain supporting cation information reasonably concerning be known ... investi equivalence the device’s substantial to a gations which have made to been show device, predicate proposed labeling for the or whether not such device is safe and effec device, any additional information re 360e(c)(1)(A). addition, § tive.” Id. In quested by the FDA. See C.F.R. 807.87. provide manufacturer must the FDA with a approved For a device to be under full design statement of manufacturing 510(k) process, the FDA must determine plans, as well as additional information new device has the same intended requested agency. See id. predicate pos use as the device and that it 360e(c)(1). Securing premarket approval technological sesses same characteristics is an time-consuming process; arduous and predicate is as safe and effective as the 1,200 requires SeOcfiXlXA).1 each average submission an See 21 device. U.S.C. "substantially equivalent” pred- 1. A device to a icate device if it: 510(k) applications, a component. In both new process signifi each advantage of specified: than use rather of a intended was manufacturers: review cant to spinal applications, average seeking clearance requires application by the time, plates they sought clearance to market the agency com only twenty hours of long 1,200 full for use in the bones required for and screws pared hours legs. AcroMed and Buckman arms and approval. 518 U.S. premarket See components were sub- that the two 478-79, 116 claimed S.Ct. predicate stantially equivalent devices ap- surgery. The FDA long used in bone B. purpose in proved for this Febru- the devices consultant regulatory is a Buckman ary 1986. manufacturers, re- and was medical device appeal plaintiffs’ subject of this act as Corporation to tained the AcroMed against Buckman. fraud on the FDA claim attempt secure FDA in its to its liaison to the AcroMed, through allege that Plaintiffs product. marketing its clearance 510(k) Buckman, misrepresentations made material process to initiated the AcroMed 510(k) to the in its successful submission orthopedic marketing clearance for its secure Specifically, plaintiffs allege that FDA. device, known as the Variable bone screw Buckman, AcroMed, (‘VSP”) through “sought approv- Spinal Fixa- Plate Screw Placement in plates al of its and screws for use VSP September In this System, in 1984.2 tion simply pretext as a in order to long bones that it intend- application, AcroMed indicated in for its true intended use market the device spinal in to market the device for use ed spine.” App. According to the the at 58. rejected request, FDA the surgery. The Buckman, plaintiffs, AcroMed and other de- determining that the device was a Class VSP they in strategy contrived a which fendants substantially equiva- III and was not device (1) misrepresent use of the intended would any predicate lent to device. (2) FDA, system the obtain the the screw 1985, AcroMed, through September In approval system to market FDA’s Buckman, application for mar- filed second (3) use, subsequent- misrepresented and 510(k) pro- keting through clearance use, spinal ly system market the for a sur- application provided in- cess. The additional they gery, for which could not obtain again about the VSP device and formation that, as a approval. FDA’s Plaintiffs contend spinal surgery. in indicated its intended use FDA, misrepresentations to the result of the again rejected application, FDA de- 510(k) issued, allowing §a was clearance termining that the device was not substan- they access to the market would devices predicate tially equivalent to a device otherwise have had. posed potential risks not exhibited that it spinal-fixation systems. other C. 1985, and Buckman In December AcroMed 510(k) 1994, seeking In Panel on Multidistrict applications final Judicial filed two court as the approval Litigation designated AcroMed the district product. market for its Orthopedic for In re: Bone split the device into its transferee court and Buckman VSP Liability Litigation, MDL No. 1014. component parts, them “nested Screw renamed 2,300 time, some civil actions have plates” and “cancerous bone screws” Since bone court. In separate application been transferred to the district and filed (i) questions safety technological and effective- characteristics raise different has the same device, predicate device. predicate ness than the as the 360c(i)(l)(A). (I) (ii) 21 U.S.C. technological characteris- has different submitted that the tics and the information device, Spine substantially equivalent predi- 2. A known as the ISOLA device is second information, appeal. including ap- System, at in this Fixation is also issue cate device contains regarding systems alleged propriate deemed Since the facts both clinical or scientific data if similar, ..., Secretary substantively necessary by are our discussion that demon- equal system applies to the ISO- with force device as safe and effective VSP strates that the device, (II) system. LA legally does not as a marketed granted a proxi- March 1995 the district court mo- fraud cannot be said to have been a brought by AcroMed other defen- plaintiffs’ mate cause of alleged injuries.” plaintiffs’ fraud on the FDA dants to dismiss App. at 158. The court reasoned that since claims, determining that those claims any misrepresentations only were directed MDA, imper- preempted were any injuries the FDA were caused missibly private implied right of action for physicians, unrelated the connection be- (Pre- App. at 28 violation of the FDCA. See alleged plaintiffs’ inju- tween the fraud and 12). Relying our trial Order No. on decision tenuous, all, ries “is so if existent at that the (3d Inc., Shiley, in Michael v. 46 F.3d 1316 former cannot said to be ‘substantial Cir.1995), purported the district court’s order causing factor’ in App. the latter.” at 159 FDA ... all fraud “dismiss[ ] (citations omitted). any pleading” claims contained the con- granting After AcroMed’s motion to dis- litigation. App. solidated at 37. claims, miss the fraud on the dis- Subsequently, Supreme June subsequently trict court granted Buckman’s Medtronic, Inc. v. Court decided identical motion dismiss “for the reasons U.S. 116 S.Ct. 135 L.Ed.2d 700 stated in Pretrial App. Order No. 845.” (1996), in which Court addressed (Pretrial 900). Thereafter, Order No. preemption scope of MDA for the first time. the district court certified Pretrial Order No. decision, plaintiffs As a result of that filed pursuant 900 as a final order to Fed.R.Civ.P. complaints amended which re-asserted fraud 54(b). (Pretrial App. See at 163 Order No. against on the FDA claims Buckman and 1067).3 other defendants. AcroMed and other de- '(cid:127) fendants filed a motion to reaffirm Pretrial jurisdiction We have over the final order of light 12 in Order No. of Lohr. Buckman pursuant the district court to 28 U.S.C. motion, joined simultaneously this but also plenary 1291. We exercise review over a filed its own motion to dismiss the fraud on claim, dismissal for failure to state and we against the FDA it. The claims district accept allegations plaintiffs all factual of the granted court AcroMed’s motion and reaf- as true and draw all reasonable inferences ^ 12, though firmed Pretrial No. Order Trump therefrom in their favor. See Hotels grounds. recog- modified The district court Resorts, Mirage & Casino Inc. Resorts likely nized that Lohr invalidated one of the (3d Cir.1998). Inc., 140 F.3d grounds prior two for its decision. Never- theless, it concluded that Lohr did not com- II. pletely undermine Pretrial Order No. 12 be- cause Lohr “did not address claims of fraud complaint I of the as Count tendered to us respect on the FDA with to the absence of a (on representative is entitled “Fraud private right of action for violations of the FDA).” (1) App. alleges at 55. It that: “[i]n App. FDCA.” at 157. The district court de- response inquiry concerning to the FDA’s allowing termined that a fraud on the FDA plates the intended use of the bone bone essentially private claim right would create screws, Buckman, acting representa- ... as that, action for violation of the FDCA and intentionally falsely tive of ... AcroMed “in prosecutorial view of the FDA’s exclusive represented [they to the FDA that ... were] any grant implied private ... discretion of an appropriate ‘intended use fractures of right contrary of action would be to the letter long upper bones of both the and lower ex- ” spirit App. of the at 153. statute.” bones,’ tremity App. flat and such other (2) 58; addition,

In “Buckman ... for the the district court determined intended plaintiffs’ components that dismissal of fraud on the FDA to clear the VSP device (3) id.; alleged upon misrepresentation,” claims was “the this warranted because based Medical, proper joint 3. Certification was for Pretrial Order No. S.N.C. and Danek Inc. submitted a 900 because asserted no other claims appendix appellees, brief and an as we treated against Buckman other than the fraud on the curiae those documents as submissions amici result, only FDA-claims. As Buckman is the appropriate order that effect. and issued Sofamor, proper party appeal. Although to this appropriate the FDA” claims was misrepresenta- “fraud on express this reliance on “[i]n forecloses, only ... if resort to state tion, federal law the FDA determined comprising those plates allegations and cancellous or if the nested bone law AcroMed’s substantially equivalent to a claim on which relief bone screws were claims do not state prior May any potentially ... of the granted devices marketed can be under represented intended use We first address the applicable state laws. 510(k) clearance, §a AcroMed” and issued of whether federal law forecloses resort issue (4) id,.; was intended exclu- “the VSP device turn to the issue of to state law and then id.; (5) spine,” “the sively for use in the allegations complaints of the whether plates and for which AcroMed’s purpose potential- may a claim under state spine,” for use in the were sold was screws ly applicable state laws. (6) id.; ignorant of the fact FDA was “[t]he components and device these devices III. by AcroMed to be used as were intended (7) devices,” 63; id. at pedicle screw fixation A. acts and it not for these fraudulent “[w]ere following preemp- The MDA contains the statements, not have issued the FDA would provision: pedicle clearances for AcroMed’s any purpose, (b) screw fixation devices Except provided as subsection have been introduced into devices would not section, political no subdivi- this State commerce, Plaintiff would not interstate or continue in sion of a State establish exposed dangerous device have been respect to a device intended for effect with implanted in Plain- surgically which was any requirement— human use id.; spine,” a direct and “[a]s tiffs from, which or in addi- is different wrongful al- proximate conduct result to, any applicable requirement under Complaint, I of this Plaintiff leged in Count device, chapter and this to the suffer, suffered, se- will continue to has and (2) safety which relates to the or effec- harm, including injury to Plain- physical vere device or to other tiveness of the spine,” id. at 63-64. tiffs applica- requirement matter included in a to track the ele- I is thus drafted Count chapter. this ble to the device under of action for of a common law cause ments § 21 U.S.C. 360k.4 (1) misrepresentation: repre- fraudulent law; fact, interpreting § opinion, regulations intention or The FDA 360k sentation of (3) part falsity; provide an intent to of the MDA in as follows: knowledge of its reliance; reliance; justifiable induce preempt- are requirements State or local (Sec- (5) resulting injury. Restatement See only Drug the Food and Adminis- ed when ond) seq. Torts 525 et of counterpart specific tration has established specific appealed, regulations or there are other re- of the decision here At the time applicable particular de- plead- quirements at the the bone eases were still screw act, thereby making any plain- is clear that the vice under ing stage. While it require- existing divergent State or local FDA” claims are based on tiffs’ “fraud on the law, applicable to the device different neither the ments rather than federal state from, to, specific in Food yet or addition parties nor court have ad- the district Drug requirements. law issues and Administration potential choice of dressed require- other or local us. note at There are State those issues are not before We outset, however, that affect devices that are not controlling state ments that they preempted ... because are not “re- representation in some law of fraudulent quirements applicable to a device” within from that in other cases be different of the act. analysis meaning [360k] of section important to our be- cases. This is following examples ...: of all The are cause the district court’s dismissal (b) grant and is not grants 360k to the preemption 4. Subsection of authority exemptions here. Human Services of Health and pertinent Secretary (1) Section does not preempt [360k] of the MDA. “Similarly, general state requirements or local general ap- State requirements common law upon by [relied plicability purpose where of the re- specifically Lohr] were not developed ‘with quirement either to products relates other respect to’ medical devices. Accordingly, (e.g., requirements addition to devices they [were] the kinds requirements codes, general such as electrical and the that Congress and the FDA feared would (warranty Uniform Commercial Code impede ability regulators federal fitness)), or to unfair practices trade implement specific and enforce federal re- requirements which the are not limited to quirements.” Id. at 116 S.Ct. 2240. devices. general obligations The imposed by the state (2) Section does not preempt [360k] common law upon by relied Lohr were “no requirements State or local equal that are more a requirements threat to federal than to, substantially to, identical require- duty would be a comply state-law with imposed by ments or under the act. prevention local fire regulations zoning 808.1(d). codes, or to C.F.R. use due care the training and supervision of a workforce. These state re- Medtronic, In Inc. v. 518 U.S. quirements escape pre-emption, therefore (1996), 116 S.Ct. 135 L.Ed.2d 700 not because the source duty a judge- Supreme applied statutory Court these rule, made common-law but rather because regulatory provisions in the context aof suit generality their leaves them outside the cate- against pacemaker manufacturer of a gory requirements 360k envisioned that had been cleared as a Class III device respect to be specific ‘with to’ devices such as 510(k). Lohr, under plaintiff there, pacemakers.” 501-02, Id. at 116 S.Ct. 2240. negligence asserted common law strict liability claims design based The Court also held that “[n]othing in pacemaker as as state well law claims based § 360k provide [a denies the right state] on defective manufacture and mislabeling. damages remedy traditional for violations of The Court held that these claims were not common-law duties when paral- those duties preempted. lel requirements.... federal presence gave preemption provision Court damages remedy of a does not amount to the of the statute a reading. narrow It stressed additional or ‘requirement’ different preemption occurs under 360k necessary statute; rather, under the it mere- (1) when there is a “requirement” state “with ly provides another reason for manufacturers (2) device;” respect to a there is a federal with comply existing ‘require- identical “requirement” “applicable to the un- device” 495, ments’ under federal law.” Id. at 116 MDA; der the requirement the state is S.Ct. 2240. from, “different inor addition to” federal the

requirement; requirement the state B. relates to the safety or effectiveness of the device or some matter in included federal the Lohr, that, apparent Based on it is requirement. 500, 518 at See U.S. 116 S.Ct. 360k, within meaning of there is no “requirement” “applicable federal to the de The Court here; found that issuance vice” at issue nor is there state 510(k) clearance ‘require’ “did not “requirement” Med- respect “with to” device. pacemaker tronic’s any particular Moreover, to take the state common upon law relied any reason; form particular agency impose any does not obligation on Buckman simply pacemaker, allowed as a device inconsistent with federal law. As substantially equivalent stress, to one that existed 18 U.S.C. 1001 it a crime to makes 1976, before to be running marketed without make a fraudulent statement to a federal gauntlet process.” of MDA agency 807.87(j) 518 U.S. and 21 requires C.F.R. 483-84,116 pro- S.Ct. 2240. The every pre-market notification to contain a cess thus no requirement established federal statement information contained “applicable to a device” within meaning therein is believed to be truthful.

824 (3d denied, Cir.), 540, 544 cert. 513 U.S. C. (1994). 429, 965, 130 L.Ed.2d 342 115 S.Ct. nor Buckman district court Neither the by bar Plaintiffs cannot circumvent this conclusions any with of these takes issue characterizing cause as a claim for their “fraud of Lohr on the concerning the effect law fraud. state in suit. The district on FDA” claims this noted, Michael, at 1329. As we have 46 F.3d Lohr was expressly acknowledged that court recognized that the first the district court grounds two it one of the inconsistent with gave holding our in Michael is reason we dismissing these originally articulated Nevertheless, it after Lohr. be- that Lohr untenable It concluded claims. nevertheless by that it remained bound our alterna- because its al- lieved consistent with dismissal was by rationale. unaffected tive ground ternative remained it, put “[w]hile As the district court Lohr. important It to note at the outset portion of may [the affected the Lohr have that, sugges contrary to the district court’s on the doc- prior court’s that relied decision] Michael, tion, in our alternative rationale like portion of the court’s preemption, trine of one, necessarily was primary our based implied absence of an reasoning based on the preemp preemption. Absent doctrine in FDCA] remains right action [under (or ground stay or law federal disagree. App. tact.” at 152-53. We abstention, here), pertinent doctrines not having jurisdiction par district court is, indeed, It well established subject ties matter cannot decline express im or Congress has not created liability imposed the relevant enforce plied private for violations of cause of action See, e.g., Na state common law. Polselli v. true, or the MDA. It is also as the FDCA Co., Mutual Fire Insurance 126 tionwide out, court, in pointed that this district court (3d Cir.1997) (“A 524, n. 1 F.3d federal Inc., 1316, Shiley, v. 46 F.3d Michael exercising diversity jurisdiction must court (3d Cir.1995), significant this fact in found law of the whose apply the substantive state that a common law holding the course of action.”). govern the Erie R. v. laws Co. against the manufacturer of a fraud claim Cf. 64, 78, Tompkins, 304 U.S. 58 S.Ct. preempted heart valve was the FDCA. (1938) (“Except gov L.Ed. 1188 matters there concluded: We byor erned the Federal Constitution Acts 360k, impose Under states dif- applied Congress, the law to be thereby requirements and reach a ferent State.”). impor case is the law of the This is than the FDA. different conclusion “ purpose ‘[t]he tant to understand because to ren- the FDA was authorized “[W]here Congress is the ultimate touchstone’ ..., it, expert and not der decision every pre-emption case.” 518 U.S. at jury judge, best suited to deter- some (quoting 116 S.Ct. 2240 Retail Clerks mine the factual issues and what their Schermerhorn, 96, 103, 375 U.S. 84 S.Ct. original con- effect could have been on its (1963)). Congress 11 179 Unless L.Ed.2d Corp., King Collagen 983 [v. clusions.” preemption, intends there is none. Accord Cir.1993) (Aldrich (1st 1130,] ] F.2d 1140 [ Congress expressed itself ingly, where has Campbell, concurring). & J.J. Under the statute, intent, “Congress’ in a preemption on MDA, authority police states have no course, primarily is from the discerned Shiley’s compliance proce- FDA’s with the language pre-emption statute and the Shiley knowingly If dures. misled ‘statutory surrounding framework’ it.” Id. at application, FDA in PMA it is for the its 486, (quoting 116 2240 Gade v. Nation S.Ct. remedy using FDA to that situation Assn., Management 505 al U.S. Solid Wastes MDA. authority Congress gave it (1992) 2374, 88, 111, 112 120 L.Ed.2d 73 S.Ct. Further, claim permitting a fraud based J., concurring)). (Kennedy, representations to the FDA would on false Michael, that In we inferred from the fact precedent conflict with our private Congress right no of action implied of action for viola- created bring not causes it Food, violations of the FDCA that intended Drug and Cosmetic Act. tions on state common law Corp., 22 foreclose suits based Optical v. Radiation F.3d Gile

825 provide remedy would for conduct fundamentally, however, More Lohr teach Ironically, plurality violative of that act. es Congress that where expressed has its Supreme Court Lohr respect drew diametri- intention with preemption, we cally opposed inference from the primarily same fact. should look to what it said. When Congress’ provide It viewed failure to it a fed- looked to what Congress 360k, §in said remedy persuasive eral as Supreme evidence of Court in Lohr concluded that preempt intent liability not to common Congress law prevent did intend to a state for the same conduct: providing from “a traditional damages reme dy for violations of common-law duties when statute, Under Medtronic’s view of the parallel those duties requirements.” federal Congress effectively precluded state courts Lohr, 495, 116 518 atU.S. S.Ct. 2240. affording state any pro- consumers Refusing to entertain Buckman’s fraudu- injuries resulting tection from from a de- misrepresentation lent claim solely because Moreover, fective medical device. because statutory scheme pri- does not contain a explicit private there is no cause of action vate cause of action equivalent would be the against manufacturers in the contained of finding preemption of state law MDA, claims suggestion and no that the Act cre- contrary to the holding clear of Lohr. In implied private action, ated an right of short, Lohr everything overrules in Michael Congress most, would have barred if not prevent plaintiff would from pursuing all, persons injured relief for by defective a cause of misrepresen- action for fraudulent

medical devices. Medtronic’s construction tation on principles.5 based common law §of 360k per- would therefore have the granting complete verse effect of immunity D. from design liability defect to an entire that, industry judgment of Con- Buekman advances preemp- a number of gress, needed more stringent regulation arguments in addition to the one provide safety adopted by order “to for the and effec- the district court. In each in- stance, tiveness of medical devices intended for we conclude rejec- that Lohr counsels use,” human (preamble 90 Stat. tion. 539

Act). is, least, say It “difficult to Buekman argues that distinguish Lohr is would, Congress believe that without com- able because it “did not involve claims ment, judicial remove all means of re- turning FDA procedures, but rather injured by course for those illegal con- product defective,” claims that the itself was duct,” Silkwood v. Corp., Kerr-McGee Buckman Br. at because the 238, 251, U.S. 104 S.Ct. 78 L.Ed.2d target alleged fraud here is “a crea (1984), and it language would take ture of statute” which responsi has the sole plainer much than the text of 360k to bility for enforcing regu the FDCA and the Congress convince us that intended that lation promulgated thereunder. Buckman result. Br. at 10.6 (foot 518 U.S. at again, S.Ct. 2240 Congress’ Once we look first to ex- omitted) (plurality). note press message concerning preemption— respectfully disagree regard (b) 5. We Except provided in this with the as in subsection of this Appeals section, conclusion reached the Court of proceedings all such for the enforce- Collagen the Seventh Corp., Circuit in Mitchell ment, violations, chapter or to restrain of this (7th Cir.1997). 126 F.3d 902 It there concluded by shall be and in the name of the United holding that our in Michael survives Lohr. 126 States. explain F.3d at 914. While it did not its conclu- provides: Section 336 sion, one can infer from its earlier decision in the Nothing chapter in this shall be construed as case, 1268, same 67 F.3d that it believes the first requiring Secretary report prosecu- to rationale for our decision in Michael retains vi- chapter tion ... minor violations of this when- tality. public ever he believes that the interest will be ' adequately by served a suitable written notice (in support 6. Buekman and amici of a similar warning. or argument) specific make reference to 21 U.S.C. 337(a) 337(a) § provides: 336. Section First, urged. text of that are it is said that the com- In the context of the 360k. not, cannot, sug- plaints allege Buckman’s do causation. as construed section Second, that, simply unpersuasive. argued it is in the context of a gested are distinctions in- Indeed, application, state a statement of the given that there must be device, respect purpose applicant, a matter requirements with to a tended as federal law, fact, representation opin- argue preemption under of is not a of it is harder to ion, Finally, argued procedures FDA than based or intention. it is 360k based on not, cannot, regu- complaints allege requirements FDA do on substantive by plaintiffs alleged on the mis- device. reliance lated by representation the FDA. possibility that not rule out the We do preemption areas of out there be some A. scope of 360k based on clear and side the requirements of direct conflicts between court determined that district The exis state law and those of the FDCA. plaintiffs’ FDA fraud on the claims should be 360k, relatively scope, tence of its narrow alleged dismissed because “the fraud cannot presumption against preemption and Lohr’s proximate to cause of be said have been law, traditionally occupied of areas state injuries.” plaintiffs’ alleged App. at 158. In however, implied in finding counsel caution view, “[l]egal largely the court’s causation preemption express preemption no ex where object plaintiffs’ fails because the of fraud-on- Here, appellees’ argument boils ists. down FDA the-FDA claim is the and not the doc litigation that the of suits of to a contention performed surgeries plain tors who on the fundamentally is inconsistent with this kind plaintiffs tiffs or the themselves.... regulatory process established alleged causal connection between the fraud inconsistency no between the FDCA. We see plaintiffs’ alleged committed on the FDA and having prerogative the exclusive tenuous, all, injuries if is so existent at bringing actions to enforce the FDCA and the former cannot be said to be a ‘substantial preserving right people plain causing App. factor’ in the latter.” at 158- position bring law tiffs’ to common fraudulent position in a 59. While we are not to canvass Moreover, misrepresentation claims. we do law, potentially applicable all the what we appellees’ apparent perception not share generally know about tort law us un makes litigation potential of such claims holds the say willing plaintiffs’ that all of the claims juries second-guessing courts and will fail for want of the of a kind causation Indeed, ample precedent, FDA. there give liability. that will rise to contexts, support premised a claim related First, alleged the mere fact that the fraud- misrepresentations on to a made federal misrepresentation ulent was made to the See, Learjet agency. e.g., Corp. Spenlin v. FDA and not the does not necessar- (1st Cir.1990) hauer, 901 F.2d 202-03 ily preclude finding legally sufficient purchaser’s against (allowing aircraft claim 310 of the causation. Section Restatement misrepresentation manufacturer on based (Second) states, example: Torts Administration); Federal Aviation Stanton misrepresentation An actor who makes a by Brooks v. Astra Pharmaceutical Prod subject liability physical to another for (3d Cir.1983) (al ucts, 718 F.2d 568-69 harm which act results from an done patient’s against drug lowing claims manu person upon ... a third in reliance FDA); misleading facturer based representation, truth of the if the actor Co., Upjohn F.Supp. Hawkins (a) (same). (E.D.Tex.1994) intends his statement induce likely

should realize that it is to induce in- person, action ... a third which IV. physical an unreasonable volves risk Buekman also asks us to affirm on the other, harm to the ground complaints that the alternative do (b) knows misrepresenta- state a claim for fraudulent (i) false, or tion. Three reasons for such a conclusion that the statement is (ii) that knowledge he the has tervening cause. It plaintiffs’ that professes. h

which e theory would be so viewed under the law of jurisdictions. some us, It is not clear to example provided by Another our deci however, that it would be so viewed under all by sion in Stanton v. Astra Pharma Brooks of the potentially applicable law. Buckman’s Products, (3d Cir.1983). ceutical 718 F.2d 553 representation to the regarding FDA intend- there, plaintiff The who had suffered brain alleged ed use is to have been intentional. damage as the result of an adverse reaction Moreover, while it alleged is not that harm to anesthetic, Xyloeaine, to the local recovered a plaintiffs intended, plaintiffs was do claim to substantial judgment against the manufac be able to show that representa- Buckman’s turer of drug. plaintiff alleged that tion was a necessary of conspiracy element a the defendant had by misled the FDA with get to exactly doctors to do plaintiffs’ what holding information it required report was physicians See, (Sec- did. e.g., Restatement concerning previously adverse effects suf ond) (“Unintended Torts 435 B Conse- fered others. We sustained judgment of quences Invasions”) of Intentional against an attack and that there legally was no B (“Intervening Force Causing sufficient causal Same Harm connection between the de Conduct”). as That Risked Actor’s misleading fendant’s plain conduct and the injury. tiffs We concluded: We do not hold that plaintiffs have or have jury heard testimony of four not alleged legally sufficient causal nexus. qualified well expert witnesses ... That issue can be resolved after the they which could ... infer that had the controlling law has been identified in each reports, had these it would have re- case. We do hold district court quired notice to the community medical in determining erred stage at this that all of PDR) (through the package insert or have failed to allege legally the critical information contained in the sufficient causal nexus. more than reports 200 adverse-reaction the incidence of cardiac respiratory arrest, notwithstanding low dosage Xy- B. locaine; physicians receiving Buckman insists that a statement of this information would have considered it 510(k) intended use connection with a in deciding how—and whether —to admin- application representation is not a of a fact or Xyloeaine ister patients. to their Resolv- but, rather, intent request authority. ing every plaintiffs’ favor, inference in we view, In its the sole interest of the FDA in cannot conclude the record was devoid applicant’s intended use is to enable it requisite quantum minimum of evi- limit authority granted to that which is supporting dence verdict. sought agency. considered In a (footnote omitted). 718 F.2d at 569 argument, related Buckman contends that We have specific earlier reviewed the alle- FDA alleged reliance on misrepresenta gations representative complaint in “negated this case ... regarding this matter causation. Plaintiffs’ nature of the given clearances that were that, theory is without Buckman’s fraudulent AeroMed,” 23, i.e., they Buckman Br. at were

representation, the FDA would giv- not have long only. limited bone use 510(k) en that, AeroMed a clearance and 510(k) clearance, absent a We, course, AeroMed would acknowledge that a state- not have access to the promote market to its ment of intended use in connection with a spinal devices for use in surgery plain- application utility has in communi- tiffs would injury. not have suffered Given cating authority sought in permitting chosen, terminology appears it to us that the FDA appropriately any authority limit the district court viewed the granted. time, causation stan- At the same we believe that dard for unintentional applicable torts as the representation such statement is a of fact regarded one and yielding plaintiffs’ necessarily important that is to the FDA as physicians promotion to AcroMed’s in- as an such. injury unreasonable risks public from put is of will be a device to which The use A manufacturer of a medical devices. regulatory scheme. in the importance

critical market for injury no access to the when has no risk new device presents that A device ap- FDA may great some kind of present any purpose absent purpose employed for one present- degree for another. of risk employed Because the injury proval. when risk 510(k) will be a function of the use by any § clearance is reason a device For this ed equiva- is thus a is a substantial the intended use put, if a device it is issued which Indeed, used for same device in the FDA review. preexisting of a focus lent central Moreover, cleared under a device its determi- nothing more material to purpose. is there 510(k) for a lawfully marketed grant access to the cannot whether nation of in the clear- specified use than the other use market. for Thus, is marketed if a device such

ance. insists, true, undoubtedly as Buckman It is may be manufacturer purpose, the another lawfully to secure unable that a manufacturer and the mar- criminally sanctioned civillyand 510(k) purpose for one clearance §§ 332. 21 U.S.C. keting enjoined. See 510(k) for to a clearance legally be entitled Buckman, requires FDA According put to a different device when the same 510(k) applicant here, however, from a representation allegation no purpose. The reads marketing intentions and regarding its to the no lawful access AeroMed had that respect to “intended with representation its it secured any purpose and that market for description of the than a representing use” as no more that it in- only by access such Implicit when, in this view is the authority sought. one use market its device for tended to a man- marketing plans of applica- that the fact, assertion intended at the time in it another, are of seeking to the market access solely ufacturer for market that device tion to an If this be taken as the FDA. no interest to manufacturer use.7 If a more hazardous Buckman, inappro- it is fact assertion of in its is successful position AcroMed’s it conflicts with stage that, this because priate scheme, marketing at its when we know complaint. Plaintiff allegations of the FDA postissuance, campaign is detected Patterson, example, alleges injunction stopping Donald G. that cam- an is entitled to misrepresentations law, it not for [the that “Were Buckman’s view of paign. Under was in re- applicant’s intended use however, enough that the FDA astute if the bones], long review, pairing fractures of the it is during its uncover the scheme 510(k) ... clearances would not have issued deny to the market powerless to access would not have any purpose, the devices accept prop- decline to place. the first We commerce, into interstate fundamentally been introduced with the at odds osition so exposed to not have been and Plaintiff would assignment. agency’s gatekeeping surgically which was dangerous device C. App. spine.” implanted in the Plaintiffs argues that on the facts Finally, Buckman alleged there was no reliance is an argument Buckman’s To the extent FDA con- to the Buckman’s statement law, for it in the we find no basis assertion of This use. This is true. statute, cerning intended regulations, in the however, not, negate possible exis- con- does briefing. To the authorities cited can be upon which relief fundamentally of a claim tence assumption is trary, such noted, § have earlier As we statutory granted. scheme. Under at odds with the (Second) suggests Torts the Restatement scheme, gatekeeper is a the FDA a fraudulent mis- someone makes protecting that when responsibility of charged with the dissenting colleague’s concern our alleged no resem- share bears 7. The situation here applicant recognizing for a intended use in an which an a statement of to one in blance 510(k) device represen- to market its clearance intends application clearance as subsequently represented, markets for for the use marketing will applicant's intentions tation of time, and, use, responds to at the same information relevant the dissemination of chill physicians requests information from direct concerning use. off-label result, we do not off-label use. As representation purpose for the of inducing any ent false evidence about similarity the of which, A, by by action A if taken will involve already screws to the approved long bone B, injury unreasonable risk of B may screws, and there dispute is no that recover resulting physical injury for even AcroMed’s screws are “substantially equiva- though he was unaware of the fraudulent lent” to the pre-existing screws. The FDA’s misrepresentation. possible It that determination that AcroMed’s screws should controlling in law one or more of these cases approved be long-bone for use has never approach. takes a similar questioned. been The basis for majority’s conclusion that V. Buckman committed fraud on the FDA is holding Our is a narrow one. We do not that in seeking long-bone approval AcroMed any plaintiffs hold that of the have stated a really and Buckman intended to market the claim under upon state law which relief could spinal is, screws for use. That once the granted.8 Neither we nor the district court screws could be sold legally for long-bone position is in a do that before identifying, use, planned AcroMed surreptitiously to in- help parties, with the governing physicians duce buy spinal the screws for Rather, law or laws. we hold that Clearly, use. if actively AcroMed marketed plaintiffs’ “fraud on the FDA” theory of lia- the screws spinal for in use violation of bility is not so at princi- odds with traditional approval FDA’s use, limited long-bone ples of tort law that Buckman is to a entitled (and AcroMed Buckman par- to the extent it dismissal of all against claims it at stage; this ticipated plan) would have violated the (2) if misrep- state law of fraudulent marketing FDA’s rule and could be held applicable resentation in one or more of accountable the FDA. A violation of the impose these cases liability would on Buck- rules, marketing however, is not fraud on the man in the alleged, circumstances law FDA; ordinary it is an transgression of an preempted by would not be the MDA. The agency’s regulatory rules. AcroMed and judgment of the district court will be re- Buckman also could be held liable doctors versed, and the case will be remanded for and, states, in patients most their if AcroMed further proceedings opin- consistent with this and Buckman told doctors that the bone ion. approved screws were spinal FDA for use or made other misrepresenta- material COWEN, Judge, dissenting. Circuit tions. But the statements made to doctors are not the majority’s theory basis for the of majority endorses a claim of “fraud on “fraud on the FDA.” contrary, To the FDA” under circumstances that will ex- majority finds fraud Buckman pose liability manufacturers to fraud AcroMed’s statement to the FDA of the in- seeking desirable product’s innovations in a purpose tended use, appli- their distort the screws penalty scheme established long-bone approval. cation for It is on this regulations, FDCA its gener- point the majority dangerous creates ate liability substantial when manufacturers confusion. respond to widely doctors’ accepted practice purchasing products medical for off-label The mere fact that AcroMed or Buckman

uses. really approval spinal wanted for the use of appreciate To how much departs this case the screws does not make request their previous from involving cases long-bone approval “fraud on the Seeking ap- fraudulent. FDA,” important it is to see agree proval what all preclude for one use should not not fraud in manufacturer, this case. When Buckman via penalty fraud liabili- sought approval from the for using ty, its seeking approval another use for bones, long screws on pres- Buckman product. did not Expanding the same the uses for hold, dissent, suggested by Nor do we explained, as controlling precedent earlier ognition FDCA, bars rec- have private stated a claim of a cause action under the regulations. MDA, under the FDA’s Plaintiffs do not implementing regula- or their and, purport to state a claim such as we have tions. innovation), Buckman and is that hibiting very desir- often be will

existing products alleg- approval long obtained bone innovation AcroMed progress and able source illegally marketing even intention of edly A manufacturer with the products. medical approval for by seeking theory, off use. Such a deliberately start for off-label the screws waiting gain ap- however, use while conventional the “intended use” state- a stretches different, potentially novel and proval a an purpose guarantee that into an all ment product. Such a highly profitable use FDA rules. violate other applicant will not have the beneficial strategy could effect majority’s position basis Under market for the in the increasing competition com- AcroMed and Buckman finding that pro- time at the same use while conventional they alleg- FDA that on the is mitted fraud negotiate it easier to to make viding revenue regula- FDA’s to violate the edly intended process. By approval FDA the arduous uses. marketing for off-label prohibiting tions “intended use” phrase reading the why that is not in hard to see It is effect man- of what the application as a declaration right action for a viola- creating private ultimately to with the seek ufacturer wants regulation, it is difficult FDA and tion of the device, simply than as a re- rather medical point with a that conclusion to reconcile (with approval specific FDA quest for a in footnote 8: “control- majority itself made requests), future nothing implied about private recognition of a ling precedent bars interpretation that is majority creates FDCA, MDA, under the cause action likely hin- and is economically unrealistic regulations.” Given implementing or their technological growth. der regulatory pro- demanding detail FDA was “de- concept that the legal The rang- cess, variety of violations the wide and company approv- desired frauded” because serious, recog- to the ing from the innocuous requested use from one al for' a different of action for violations of nizing a state cause ultimately approved particularly is hard and pen- greatly regulations FDA will distort FDA case. Before the in this to sustain by the statute. The alty established scheme bones, it had long approved the screws a violation of the FDA’s penalties attached to rejected Buckman and previously twice substantially in- often be regulations will spinal use. Those applications for AeroMed’s creased, of violations no enforcement will and unmistakably clear applications made prior prosecuto- by the FDA’s longer be controlled Buckman and AcroMed FDA that to the rial discretion. spi- approval choice as their first wanted decep- no There was nal use of the screws. majority’s position problematic goals. The AcroMed’s ultimate tion about respect. The FDA closely related another assuredly clearance knew what FDA most recog- community long have medical and the granted clearance was sought and what was off-label importance of doctors’ nized the or denied. (uses products not indicated uses of medical FDA). approved or See on the label that what distin- majority may believe FDA, Azari, D. M. Beck & Elizabeth James company where a case from one guishes this Use, De- Consent: real- approval for one use while simply seeks Informed Off-Label (and Misconceptions, 53 Food bunking Myths and for another hence ly wanting approval (1998).1 may, in Doctors Drug L.J. 72 flatly pro- & this from prevents what decision circumstances, and accepted in certain ate and rational explains "It is an article that: 1. The therapy approaches drug may, in fact reflect determines that a principle FDA [the] that once marketed, extensively reported in medical physician's been that have drug or device can be drugs already (the on Valid new uses for product practice literature... discretionary use of that through medicine) first discovered the market are often uses indicated not restricted to the therapeutic serendipitous inno- observations wide- FDA-regulated labels. Off-label use is Azari, supra, With at 77. community ...” Beck & vations spread and often is in the medical care, particular, the article regard screws in optimal to bone giving patients medical essential to FDA, ethic[isls], following the FDA in a quotes statement [the] medical both of which Drug Azari, publication Adminis- supra, titled Food recognize.” Beck & court most tration, practice, Update "In on Pedicle Screws: points the FDA stated out that 72. The article orthopedic FDA surgeons screws which "‘unapproved’ often use Drug that: Bulletin pedicle purposes ... as other may appropri- has cleared for precisely 'unlabeled' uses more professional judgment, developed, of their FDA response the exercise Congressional hearings decide that based on current medical re- ensuing confusion over an FDA unapproved product search an use of a best concept paper, a twelve-factor test to decide patient’s serves a needs. manufacturer-sponsored when a CME semi nar violated the FDA’s rules on marketing. Permitting off-label uses seem anoma- Washington Legal See Foundation v. Fried given labeling lous that the FDA’s and mar- man, 94-1306, No. 1998 WL *4 keting prevent companies restrictions (D.D.C. 1998) (FDA July unconstitution actively pursuing an off-label market. More- ally speech restricted commercial because over, authority the fact that lacks less restrictive means of achieving gov regulate practice might imply of medicine available). ernment’s interest were As is that uses amount to an end-run off-label by complexity illustrated both the of the authority. agency’s around the But the FDA’s test and its efforts to hone its re position FDA’s own on off-label use reveals sponse, difficult and balancing subtle is called part that off-label uses are a valuable in evaluating for manufacturers’ in roles the practice difficulty of medicine.2 The not con- creation and distribution of information about majority fronted the is that there is a drugs off-label uses of and medical devices.3 very endorsing real tension created between problem easily is not dismissed. it Once preventing marketing off-label uses but for accepted desirable, is that off-label uses are questions those uses. Close will be raised it is difficult to maintain that doctors should simply about whether a manufacturer was be shielded from truthful information con responding to doctors’ desirable demand for cerning when product and how to use a for uses, off-label or whether a manufacturer an off-label use. Patients will benefit impermissibly trying was an off- create having their doctors informed about off-label reg- label market and circumvent the FDA’s uses. ulation. As matters stood before this deci- sion, police boundary the FDA was left to Contrary majority’s position, to the permissible impermissible between re- problem allowing juries of to determine when sponses majority’s to off-label demand. The a improperly manufacturer has advertised an however, theory, jury now throws into the impose off-label use is not that it will too question box the unacceptable of when “mar- rule, stringent chilling a dissemination of keting” place. has taken uses; valuable information about off-label it jury problem

Consider also decisions lack the consisten- deciding when cy impermissible “marketing” agency-enforced apart of an place has taken rule. Even manufacturer-sponsored continuing restricting from the harm of medical beneficial infor- (“CME”). uses, education After manufacturers mation about off-label and the need began years financially consistently recent underwrit- enforced rule wherever the materials, ing drawn, more CME seminars and jury’s liability line is assessment of screws. Such use of medical drugs devices for non- tribute information about off-label uses of approved purposes traditionally regu- has been provided requirements and devices certain are hospitals physicians lated practice in which the Among requirements drug, met. instance, Azari, and not the FDA.” Beck and is that the manufacturer must have supra, at 77. new, application approval submitted Thus, off-label use. manufacturers are allowed Kessler, Washington Legal 2. See Foundation applications to submit for new uses and to 26, (D.D.C.1995), dis- F.Supp. hingt 28 n. 1 Was Friedman, 94-1306, Legal tribute certain information about the off-label Foundation v. use No. (D.D.C. 30, 1998) July 1998 WL application at *3 while an for the off-label use is still supra note 1. pending. majority's theory, On the will the man- FDA, ufacturer have fraud committed on the which, effective, legislation 3. Recent once will notwithstanding statutory provisions, the new if supersede distributing the FDA’s restriction on use, approval the manufacturer secures for one printed incongruity material underscores the compli- distributes materials on off-label uses in majority's position. Drug The Food and statute, ance with the and does so while its 105-115, Modernization Act of Pub.L. No. primary objective (to approval is to obtain for the 111 Stat. 2296 be codified at 21 U.S.C. 360aaa, seq.) permits et pending manufacturers to dis- off-label use with the FDA? mar- engaged improper has lia- manufacturer Massive in a third sense: problematic provide a consistent they FDA would will fail to keting, where the bility imposed bewill misconduct, standard, exchange the cost of of infor- valuable inhibit not find needlessly raised. uses, needlessly bewill raise medical devices off-label mation on It devices. price drugs and medical respond, as simply to question begs It intended very unlikely Congress seems a manu- majority in footnote does much to intrude so cause of action a state actually it liability when face facturer will not regu- of the FDCA’s both in the enforcement listed in the use” for the “intended markets severity latory requests for scheme answers application and prob- to a violation. penalties uses. attached about off-label information liability permits majority lem remains: vehemently, dis- respectfully, but I most jury concludes the FDA when for fraud on sent. impermissible manufacturer conducted that a demonstrating that the marketing, manufac- FDA in its statement

turer “defrauded” Presumably, ma- purpose.

of intended juries’ interpre-

jority’s response is not that pose prob- “marketing” limited will

tations can insulate a manufacturer

lems because liability on the FDA from for fraud

itself for the intend- simple making act of sales That application. listed in the ed use distinction, why very like a wooden seems America, UNITED STATES important from the be so those sales should Plaintiff-Appellee, liability on the FDA? standpoint of for fraud marketing? If the problem illegal Isn’t the any showing of require majority does Anthony Wayne ALLEN, Michael a/k/a liability justi- can illegal marketing, how Defendant-Appellant. Washington, prohib- the rule will be The effect of fied? making en- otherwise it manufacturers No. 97-4100. off-label tirely responses to demand for legal accepts uses, FDA itself responses that the Appeals, States Court United worse, the rule will Or even as desirable. Circuit. Fourth uses directly prohibit innovation very by triggering fraud drugs and devices 8,May 1998. Argued ap- application is filed for liability when an it is admitted proval of a new use. Once Sept. Decided theory illegal mar- majority’s focuses on prob- all the are thrown back on keting, we

lems listed above. majority demonstrate

Nowhere does theory on the new of fraud

the need for its com- adequately can be

FDA. The existing law under

pensated their doctors demonstrated; the de- any malpractice they if held liable for fraud

fendants can be they approval had

told doctors not; FDA remains free

they and the did mar- impermissible it feels

prosecute when also place. Manufacturers

keting has taken liability law. product

can be held liable under sum, juries permitted to dis- are

In when whether judgment FDA’s about

place the

Case Details

Case Name: In Re ORTHOPEDIC BONE SCREW PRODUCTS LIABILITY LITIGATION, Plaintiffs Legal Committee, Appellant

Court Name: Court of Appeals for the Third Circuit

Date Published: Nov 17, 1998

Citation: 159 F.3d 817

Docket Number: 97-1783

Court Abbreviation: 3rd Cir.